Clinical Trial Update: Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating safety and efficacy of different dose levels of pasireotide in patients with de novo, persistent or recurrent Cushing's disease; result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cushing Disease

Drugs mentioned

• Pasireotide (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Cushing's Disease | Phase 3 | Status: COMPLETED | Results posted: 2013-02-06